The RASopathies are a group of clinically related disorders caused by germline mutations in a number of genes that encode components or regulators of the Ras/Mitogen Activated Protein Kinase (Ras/MAPK) signalling pathway. These disorders include Noonan syndrome, cardiofaciocutaneous (CFC) syndrome, Noonan-like syndrome with multiple lentigines, Mazzanti syndrome, Costello syndrome, neurofibromatosis type 1 (NF1), and Legius syndrome. Each RASopathy exhibits characteristic features, and shares a common mechanism of Ras/MAPK pathway dysregulation and overlapping clinical manifestations. These may include a wide spectrum of cognitive deficits, cardiac malformations, similar facies, postnatal reduced growth, and an increased risk of cancer. 1 The Ras/MAPK pathway is well known for its role in oncogenesis and tumour progression and is critically involved in the regulation of the cell cycle. 2 Intellectual impairment and psychiatric morbidity are known to be common in the RASopathies but have only been systematically studied to date in NF1. 3 Within the other RASopathies, NF1 aside, Noonan syndrome is the most common and most phenotypically variable, estimated to affect between 1 in 1000 to 2000 newborn infants. 2 It is a genetically heterogenous disorder, most frequently caused by mutations in PTPN11. Mutations in a number of other genes can also cause Noonan syndrome, sometimes with a gene specific phenotype (e.g. SOS1, RAF1, SHOC2, RIT1, CBL, KRAS, NRAS, and BRAF). Mutations in several other genes (RRAS, RASA2, A2ML1, SOS2, LZRT1) have been recently reported in small numbers of patients, but their role remains under investigation. 4 CFC syndrome is a rare disorder, caused by mutations in BRAF, MAP2K1, MAP2K2, or KRAS. It affects growth and development more severely than Noonan syndrome but systematic studies describing the cognitive-behavioural phenotype are still in their infancy. Costello syndrome is a rare disorder caused by mutation in HRAS, which has the highest risk of cancer amongst the RASopathies. Costello syndrome is associated with mild to moderate intellectual disability and poor adaptive functioning.
Emerging evidence suggests the importance of the Ras/ MAPK signalling pathway in autism spectrum disorders (ASD). 5 Within autism studies, Pinto et al. 5 have shown that genes most affected by copy number variations and single nucleotide variations converge on three neural system functional networks which include the Ras/MAPK signalling pathway. Studies investigating the behavioural phenotype in Noonan and CFC syndromes describe ASDlike symptomatology and traits. For instance, in a prospective observational study of 112 adults, Shaw et al. 6 found that poor quality of life in Noonan syndrome was related to lack of social life and inability to fit in. More recently, Adviento et al. investigated the prevalence of autistic symptomatology in children and adults (age range 1-73y) using the Social Responsiveness Scale (SRS) and Social Communication Questionnaire (SCQ) in NF1 (n=81), Costello (n=44), Noonan (n=52), and CFC (n=54) syndromes, and found significant ASD traits of 11 per cent in NF1, 21 per cent in Noonan syndrome, 26 per cent in Costello syndrome, and 54 per cent in CFC syndrome. 7 Similarly, Alfieri et al. 8 used the SCQ and Modified Checklist for Autism in Toddlers (M-CHAT) to investigate autistic symptomatology in 70 patients (age range 2-28y) with RASopathies (Noonan syndrome n=38, CFC syndrome n=11, Costello syndrome n=21) and found significant ASD traits in 12 per cent with Noonan syndrome, 44 per cent in Costello syndrome, and 64 per cent in CFC syndrome. All of these studies are therefore suggestive of the presence of ASD-like symptomatology but are severely limited by the lack of detailed ascertainment and the absence of indepth, criterion standard ASD phenotyping instruments. Comorbid cognitive and behavioural problems are known to impact the specificity of quantitative phenotypic measures such as the SRS, thus limiting interpretation of the findings on that instrument. 9 The aim of this study is to investigate the neurobehavioural phenotype of the rare disorders of the Ras pathway -Noonan, CFC, and Costello syndromes -and, in particular, to investigate systematically the nature and severity of social impairment and ADHD using detailed in-person phenotyping.
METHODS Participants
Participants were recruited between January 2014 and November 2014 from the Clinical Genetic Service in the Manchester Centre for Genomic Medicine. Participants were approached consecutively. The study was also advertised on newsletters, family information days, and on the social media of Noonan, Costello, and CFC syndrome charities. The inclusion criteria for the current study were (1) clinical diagnosis of Noonan, Costello, or CFC syndrome, made by a clinical geneticist, and (2) participants aged between 6 years and 16 years. Medical notes were reviewed to confirm the diagnosis. When mutation testing had been performed, mutation status was confirmed. Eligible participants were sent study information sheets and 'consent to contact' forms. This study was given approval by South Manchester Research Ethics Committee, approval number 10/H1003/77.
Measures and procedures
The Wechsler Abbreviated Scale of Intelligence-II (WASI-II) and Mullen Scales of Early Learning were used to assess intellectual functioning, parent-rated Behaviour Rating Inventory of Executive Function (BRIEF) as a measure of executive function, Autism Diagnostic Interview-Revised (ADI-R) parent interview and Autism Diagnostic Observation Schedule-2 (ADOS-2) was used to assess social communication impairments, Conners Parent Rating Scale-3rd Edition Short Form as a measure of ADHD symptomatology, Test of Everyday Attention for Children (TEA-Ch) as a measure of attention, Diagnostic Analysis of Nonverbal Accuracy (DANVA) to assess ability to identify facial expressions, and Test Observation Form (TOF) as a measure of researcher-rated behaviour. Detailed information about the measures, procedures, and diagnostic classifications of ASD and ADHD is provided in Appendix S1 (online supporting information).
Statistical analysis
Data were analysed in SPSS version 17 (SPSS Inc., Chicago, USA). For the Noonan syndrome and CFC syndrome groups, the group means and standard deviations were calculated for Full-scale IQ, BRIEF, and TEA-Ch measures including the rate of children scoring in the clinically impaired range. For the Noonan syndrome group, the means and standard deviation of ADI-R subdomains, ADOS, Conners, TOF, Full-scale IQ, and DANVA across the three subgroups (ASD, broad ASD, and non-ASD) are described. Intelligence quotient and ADHD symptoms across the three subgroups were compared using non-parametric Kruskal-Wallis test. A two-tailed p-value of less than 0.05 was considered significant. For the CFC group, the means and standard deviations of the ADI-R domains, ADOS, Conners, and TOF are described.
RESULTS

Patient demographics
Fifty children (30 males, 20 females) received in-depth assessment. Mean age was 10 years and 4 months (standard deviation [SD] 2y 9mo, range 6y-16y 9mo) and mean IQ was 81 (SD 19.2, range 33-120). Forty children had a diagnosis of Noonan syndrome; mean age was 10 years and 10 months (SD 2y 9mo, range 6y-16y 9mo), 25 males and 15 females. Of these, 16 out of 40 had a Special Educational Needs (SEN) Statement (a statutory document that sets out the additional educational help that a child What this paper adds
• Both autism spectrum disorder and attention-deficit-hyperactivity disorder are highly prevalent in the RASopathies.
should receive in order to progress in school). Three had pre-existing diagnoses of ASD and one had a diagnosis of ADHD.
Nine children had a diagnosis of CFC syndrome; mean age of the CFC group was 10 years and 1 month (SD 3y, range 6y 3mo-15y 7mo), five males and four females. Of these, eight out of nine had a SEN Statement. None of the children had a pre-existing diagnosis of ASD or ADHD. There was only a single child with Costello syndrome, and so the results for this child are not included below, although the results were shared with the family.
Genetic status
In the Noonan syndrome group, 21 participants had mutations in PTPN11, one in SOS1, one in CBL, two in SHOC2, one in KRAS, and two in RIT1; the mutation status of 12 participants was unknown. In the CFC group, eight had a BRAF mutation and one had a mutation in MAP2K1.
Intelligence and executive functioning (Table I) Intelligence was measured using the WASI-II in 39 of the Noonan syndrome group and six of the CFC group. The Mullen Scale of Early Learning was used in one participant in the Noonan syndrome group and three in the CFC group.
In the Noonan syndrome group, mean overall IQ was 87 (SD 13.9, range 61-120); three out of 39 (7.7%) had Full-scale IQ below 70. In the CFC group, mean IQ using the WASI-II was 73.9 (SD 20.1, range 45-100), mean verbal IQ 79.5 (SD 23.5), performance IQ 65.8 (SD 16.8); three out of six (50%) had Full-scale IQ below 70. The Mullen was used in three of the CFC sample; mean receptive language T scores on Mullen were 25.67 (SD 5.13) and mean expressive language T scores 22.00 (SD 3.46).
Overall executive function was assessed using the BRIEF questionnaire (Table I ). In the Noonan syndrome group, 42.8 per cent had clinically significant impairments in executive functioning with the biggest deficits seen in the working memory and initiation domains. In the CFC group, 66.7 per cent had clinically significant deficits in executive function.
ASD assessment Noonan syndrome group
Using the CPEA criteria, 12 children (30%; 10 males, two females) met the criteria for ASD, 12 (30%; eight males, four females) for broad ASD, and 16 (40%; seven males, nine females) children as non-ASD. Table II shows the detailed scores on all ascertainment instruments grouped by diagnostic category. There is no overall difference in IQ across the three groups. There were no significant differences between the three groups on the rates of ADHD symptomatology on parent-and researcher-rated measures. On the DANVA, total errors were highest in the ASD group, followed by broad ASD and non-ASD. Similar ordering across the groups was seen for errors on high and low intensity facial expressions.
CFC group
Eight out of nine children (88.9%; four males, four females) met the criteria for ASD, one out of nine for broader ASD using the CPEA criteria. On the ADI-R, the mean scores of the CFC sample across the three domains were as follows: social interaction 18.00 (SD 5.89), communication 14.56 (SD 4.10), and RRBs 5.56 (SD 2.45). On the ADOS, the mean scores on social affect domain were 8.22 (SD 5.09) and RRB was 4.00 (SD 1.41). The mean ADOS total scores were 12.22 (SD 5.19) . DANVA data was available for six participants with CFC syndrome; mean total error score on DANVA were 11.17 (SD 5.35), mean high intensity error score 4.67 (SD 2.73), and mean low intensity error 6.0 (SD 2.68).
ADHD
Noonan syndrome group
On the parent-rated Conners questionnaire, 30 out of 40 (75%) had clinically significant scores for inattention, 27 out of 40 (67.5%) for hyperactivity, and 67.5 per cent had clinically significant scores on both domains. On the researcher-rated TOF, 14 out of 40 (35%) had T scores greater than 70 on inattention domain, 14 out of 40 (35%) on hyperactivity domain, and 15 out of 40 (37.5%) had T scores greater than 70 on ADHD index. On the TEA-Ch subtests (Table I) , significant impairments (defined as 1 SD below mean or age scaled scores <7) were seen in 46.9 per cent on Score subtest, 59.4 per cent on Sky Search dual task, 40.6 per cent on Sky Search, and 34.3 per cent on Creature Counting. Triangulating the results from the three instruments (TEA-Ch, Conners, and TOF instruments; see Appendix S1), 21 out of 40 children (52.5%) with Noonan syndrome were rated to have significant ADHD.
CFC group
On the parent-rated Conners, all participants had clinically significant T scores for inattention and 8 out of 9 (88.9%) for hyperactivity on the Conners. On the researcher-rated TOF, 6 out of 9 (66.7%) had T scores greater than 70 on inattention, 6 out of 9 (66.7%) on hyperactivity, and 7 out of 9 (77.8%) on combined ADHD index. On the TEA-Ch in the CFC group, significant impairments were seen in 100 per cent on Score subtest, 100 per cent on Sky Search dual task, 50 per cent on Sky Search, and 50 per cent on Creature Counting. Triangulating the results on the three instruments, all participants with CFC syndrome were considered to have significant ADHD.
Other comorbidities
On the TOF in the Noonan syndrome group, 19 out of 40 (47.5%) had significant scores for internalizing disorders and 24 out of 40 (60%) for externalizing disorders. In the CFC group, 7 out of 9 (77.8%) had significant scores for internalizing disorders and 8 out of 9 (88.9%) for externalizing disorders.
DISCUSSION
To our knowledge, this is the first study to rigorously assess the neurobehavioural phenotype in Noonan and CFC syndromes using criterion standard, in-depth ASD phenotyping measures. The estimated prevalence of ASD in the Noonan syndrome group is 30 per cent with a further 30 per cent showing partial features. These prevalence rates are substantially higher than previously reported estimates using parent-rated questionnaire measures. 7, 8 The Full-scale IQ in the Noonan syndrome ASD group was within the normal range and not significantly different to the broad ASD and non-ASD group, which implies that the social impairments in Noonan syndrome group cannot be explained on the basis of cognitive deficits (Table II) . As in non-syndromic ASD, within our Noonan syndrome group we found a preponderance of ASD in males with a sex ratio of 5:1; these rates are comparable to the findings in non-syndromic ASD. 10 The CFC group showed significant levels of cognitive impairment but near complete prevalence of ASD. Within this small CFC sample, the sex bias was not evident with a 1:1 sex ratio for the prevalence of ASD. Lack of ASD sex bias has been described in other genetic disorders, such as tuberous sclerosis 11 and Cornelia De Lange syndrome, 12 which are associated with significant levels of intellectual impairment.
Overall intellectual functioning in the Noonan syndrome group was comparable to previously reported studies. 13, 14 Executive functioning assessed using parent-rated BRIEF measure suggested clinically significant executive functioning deficits in 42 per cent of the Noonan syndrome group and 66 per cent of the CFC sample. The largest deficits were seen in the two subtests (Score! and Sky Search Dual Task) measuring sustained attention, similar to the findings reported by Pierpont et al.
14 Deficits in sustained attention on the TEACh have also been found in children with idiopathic ADHD; Heaton et al. 15 investigated the use of TEA-Ch in 63 children with ADHD compared to non ADHD controls and found that the ADHD group performed significantly worse on sustained attention and attentional control but not on selective attention. These findings therefore suggest that the ADHD symptomatology in Noonan and CFC syndromes are phenomenologically similar to idiopathic ADHD.
In other comorbidities, we found higher rates of internalizing and externalizing disorders than previously reported. 8 On researcher-rated TOF, we found 47.5 per cent of the Noonan syndrome group and 77.8 per cent of the CFC group had significant rates of internalizing disorder. Similarly 60 per cent of the Noonan syndrome group and 88.9 per cent of the CFC group had significant rates of externalizing disorders.
How clinically significant are these findings? The NIHCD CPEA criteria produce categories equivalent to clinical diagnoses, with the broad ASD group containing partial traits that are considered also as having clinical significance. 16 There does not appear to be any unusual pattern of ASD symptoms within the Noonan syndrome or CFC groups. Moreover, as in idiopathic autism, the Noonan syndrome and CFC groups show difficulties in recognition of facial expressions particularly on low intensity expressions. 17 Idiopathic autism shows a striking male preponderance in a ratio of 4:1 but in samples with intellectual disability, males and females are more equally represented. 18 ASD sex ratios of 5:1 in Noonan syndrome and 1:1 in CFC syndrome thus mirror the findings in idiopathic autism literature. These results are therefore suggestive of phenomenological similarities of ASD in Noonan syndrome and CFC syndrome with idiopathic ASD.
Given the extreme variability and underdiagnosis of Noonan syndrome and the extreme rarity of CFC and Costello syndromes, and hence their patchy geographical spread throughout the UK, it was not possible to do systematic population-based ascertainment of the kind we undertook in our NF1 study. 19 The recruitment of the sample through clinic referral and self-referral from advertisement through charity networks inevitably produces the possibility of referral bias in the sample and ascertainment bias in the results and is a limitation regarding representativeness. The same difficulties are also inherent in previous questionnaire-based studies of these disorders. Further systematic study using complementary sampling methods will be useful to test replication of the results. Other limitations of the study include small sample sizes, in particular of the CFC group. Nonetheless despite the genetic heterogeneity of the sample, there appears to be a consistent set of behavioural symptomatology in these individuals with disorders affecting the Ras/MAPK pathway.
Mutation status was known in 28 of the 40 patients with a clinical diagnosis of Noonan syndrome. The NSEuronet database (https://nseuronet.com/php/) contains mutation information on 1714 patients with Noonan syndrome. In that cohort, PTPN11 mutations account for 61 per cent of patients, SOS1 16 per cent, RAF1 7 per cent, RIT1 3 per cent, and all other genes less than 1 per cent. Although the small numbers make direct comparison impossible, the relatively high proportion of PTPN11 mutations in the mutation positive patients in this cohort (75%) may reflect that the fact that cognitive and behavioural difficulties are more common in Noonan syndrome because of PTPN11 mutations. Further study will be required to determine the frequency of neurobehavioural difficulties with specific genotypes.
The strengths of this study are the use of rigorous, criterion standard measures of psychopathology, including triangulation between parent-rated, in-person child assessment, and researcher-rated measurements. These methods minimize rater biasing of results and make our results comparable with similar studies of other related disorders, which will be crucial in order to learn about which aspects of phenotype may be specific to particular disorders or general across them.
The Ras/MAPK pathway is well studied in cancer and is considered an attractive therapeutic target for cancer treatment. 20 The results from this study complement our similar approach to measurement of ASD and ADHD in NF1, 19 offering empirical support that multiple members of a well-defined biochemical pathway contribute to ASD. The Ras/MAPK pathway has thus the potential to provide a unifying theory of autism, 21 with the possibility of targeted interventions capable to ameliorating the neurobehavioural phenotype. 22 From a clinical perspective, these findings add important specificity to the knowledge about the clinical psychopathology of the disorders. The high prevalence of ASD and cooccurrence of ADHD have important implications for clinical management and educational planning. Our data on preexisting diagnosis make it clear that ASD and ADHD are underrecognized in these groups possibly because of 'diagnostic overshadowing', where the behavioural difficulties are ascribed to the primary disorder itself. Our findings suggest that screening for ASD and ADHD should be undertaken in all children with Noonan and CFC syndromes, and that these developmental disorders should be considered as part of the differential diagnoses when children present in the clinic with problems of behaviour, social adjustment, or relationships.
